Nov 6, 2026 · 29 min
Midterm gains collide with fertility medicine’s evidence gap
420: Democrats’ midterm victory, and a questionable fertility procedure
The episode connects a Democratic congressional victory’s potential health-policy consequences with the risks patients face when experimental fertility procedures outrun evidence and oversight.
- 1Democratic gains could reshape drug pricing, Medicaid, NIH funding, FDA regulation, and oversight of HHS Secretary Robert F. Kennedy Jr.
- 2Clinics market mitochondrial replacement therapy to older women despite limited evidence that it addresses age-related egg abnormalities.
- 3Weak regulation and overseas success claims leave patients paying tens of thousands of dollars without reliable evidence of benefit.
Don't miss
Megan Molteni explains why patients pursue an expensive overseas procedure despite limited evidence, disputed success claims, and weak oversight.
The brief
The episode opens with two health stories: what Democratic midterm gains could mean for drug pricing and federal agencies, and why older women are traveling abroad for three-parent IVF.
Reporter Daniel Payne examines how the Democratic Party’s congressional victory could affect pharmaceutical companies, Medicaid, NIH policy, FDA regulation, and HHS Secretary Robert F. Kennedy Jr.
Reporter Megan Molteni investigates mitochondrial replacement therapy, which combines genetic material from three people and is marketed as a fertility treatment despite limited evidence for age-related egg abnormalities.
Patients spend tens of thousands of dollars abroad amid intense demand, stigma concerns, and disputed clinic success claims, while weak oversight makes poor care difficult to assess.
The central tension is whether MRT should expand through fertility tourism or proceed through regulated trials focused on patients with specific IVF failures or inherited mutations.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.